New drug cocktail shows promise against rare cancers
NCT ID NCT03526679
First seen Jan 03, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tested a combination of two drugs, lenvatinib and eribulin, in 30 adults with advanced sarcoma (a type of cancer) that could not be removed by surgery or had spread. The goal was to see if the combo could shrink tumors or stop them from growing. Participants had already received up to two prior chemotherapies. The study measured tumor changes using scans and tracked how long patients lived without the cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan
Conditions
Explore the condition pages connected to this study.